Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer

J. D. Hurt, D. L. Richardson, L. G. Seamon, J. F. Fowler, L. J. Copeland, D. E. Cohn, E. Eisenhauer, R. Salani, D. M. O'Malley

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Objective: To determine efficacy, toxicity, and survival in patients with recurrent epithelial ovarian cancer (EOC) receiving combination of weekly paclitaxel and biweekly bevacizumab (PB). Methods: We reviewed chemotherapy logs identifying all patients receiving combination PB. Toxicities were graded using CTCAEv3.0 criteria. Response rates (RR) were measured using RECIST criteria or by CA-125 levels per modified Rustin criteria. RR and progression-free survival (PFS) were determined and plotted using Kaplan-Meier survival analysis. Results: Fifty-one patients receiving at least two cycles of chemotherapy were evaluable for survival and 55 patients receiving one cycle of PB were evaluable in toxicity analysis. The mean number of previous regimens was four. The overall median PFS was 7 months and median OS was 12 months. The overall response rate (ORR) was 60% (CR 25% and PR 35%). Median PFS for complete and partial responders were 14 and 5 months respectively. Stable disease was seen in 26% with median PFS of 6 months. Thirteen experienced treatment delays for a variety of factors. The most G3/4 toxicities were fatigue (16%), hematologic (9%) and neurotoxicity (7%). Three patients (5%) experienced bowel perforations. Conclusions: Combination of paclitaxel and bevacizumab is feasible and demonstrates an acceptable toxicity profile and a high response rate. These observations should be useful in planning future clinical trials with this combination therapy.

Original languageEnglish (US)
Pages (from-to)396-400
Number of pages5
JournalGynecologic Oncology
Volume115
Issue number3
DOIs
StatePublished - Dec 2009

Fingerprint

Paclitaxel
Ovarian Neoplasms
Disease-Free Survival
Drug Therapy
Survival
Kaplan-Meier Estimate
Survival Analysis
Fatigue
Bevacizumab
Clinical Trials
Therapeutics

Keywords

  • Biologics
  • Chemotherapy
  • Monoclonal antibodies
  • Ovarian cancer

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer. / Hurt, J. D.; Richardson, D. L.; Seamon, L. G.; Fowler, J. F.; Copeland, L. J.; Cohn, D. E.; Eisenhauer, E.; Salani, R.; O'Malley, D. M.

In: Gynecologic Oncology, Vol. 115, No. 3, 12.2009, p. 396-400.

Research output: Contribution to journalArticle

Hurt, JD, Richardson, DL, Seamon, LG, Fowler, JF, Copeland, LJ, Cohn, DE, Eisenhauer, E, Salani, R & O'Malley, DM 2009, 'Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer', Gynecologic Oncology, vol. 115, no. 3, pp. 396-400. https://doi.org/10.1016/j.ygyno.2009.08.032
Hurt, J. D. ; Richardson, D. L. ; Seamon, L. G. ; Fowler, J. F. ; Copeland, L. J. ; Cohn, D. E. ; Eisenhauer, E. ; Salani, R. ; O'Malley, D. M. / Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer. In: Gynecologic Oncology. 2009 ; Vol. 115, No. 3. pp. 396-400.
@article{08454cb22591419ca8956ae0048fabb0,
title = "Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer",
abstract = "Objective: To determine efficacy, toxicity, and survival in patients with recurrent epithelial ovarian cancer (EOC) receiving combination of weekly paclitaxel and biweekly bevacizumab (PB). Methods: We reviewed chemotherapy logs identifying all patients receiving combination PB. Toxicities were graded using CTCAEv3.0 criteria. Response rates (RR) were measured using RECIST criteria or by CA-125 levels per modified Rustin criteria. RR and progression-free survival (PFS) were determined and plotted using Kaplan-Meier survival analysis. Results: Fifty-one patients receiving at least two cycles of chemotherapy were evaluable for survival and 55 patients receiving one cycle of PB were evaluable in toxicity analysis. The mean number of previous regimens was four. The overall median PFS was 7 months and median OS was 12 months. The overall response rate (ORR) was 60{\%} (CR 25{\%} and PR 35{\%}). Median PFS for complete and partial responders were 14 and 5 months respectively. Stable disease was seen in 26{\%} with median PFS of 6 months. Thirteen experienced treatment delays for a variety of factors. The most G3/4 toxicities were fatigue (16{\%}), hematologic (9{\%}) and neurotoxicity (7{\%}). Three patients (5{\%}) experienced bowel perforations. Conclusions: Combination of paclitaxel and bevacizumab is feasible and demonstrates an acceptable toxicity profile and a high response rate. These observations should be useful in planning future clinical trials with this combination therapy.",
keywords = "Biologics, Chemotherapy, Monoclonal antibodies, Ovarian cancer",
author = "Hurt, {J. D.} and Richardson, {D. L.} and Seamon, {L. G.} and Fowler, {J. F.} and Copeland, {L. J.} and Cohn, {D. E.} and E. Eisenhauer and R. Salani and O'Malley, {D. M.}",
year = "2009",
month = "12",
doi = "10.1016/j.ygyno.2009.08.032",
language = "English (US)",
volume = "115",
pages = "396--400",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer

AU - Hurt, J. D.

AU - Richardson, D. L.

AU - Seamon, L. G.

AU - Fowler, J. F.

AU - Copeland, L. J.

AU - Cohn, D. E.

AU - Eisenhauer, E.

AU - Salani, R.

AU - O'Malley, D. M.

PY - 2009/12

Y1 - 2009/12

N2 - Objective: To determine efficacy, toxicity, and survival in patients with recurrent epithelial ovarian cancer (EOC) receiving combination of weekly paclitaxel and biweekly bevacizumab (PB). Methods: We reviewed chemotherapy logs identifying all patients receiving combination PB. Toxicities were graded using CTCAEv3.0 criteria. Response rates (RR) were measured using RECIST criteria or by CA-125 levels per modified Rustin criteria. RR and progression-free survival (PFS) were determined and plotted using Kaplan-Meier survival analysis. Results: Fifty-one patients receiving at least two cycles of chemotherapy were evaluable for survival and 55 patients receiving one cycle of PB were evaluable in toxicity analysis. The mean number of previous regimens was four. The overall median PFS was 7 months and median OS was 12 months. The overall response rate (ORR) was 60% (CR 25% and PR 35%). Median PFS for complete and partial responders were 14 and 5 months respectively. Stable disease was seen in 26% with median PFS of 6 months. Thirteen experienced treatment delays for a variety of factors. The most G3/4 toxicities were fatigue (16%), hematologic (9%) and neurotoxicity (7%). Three patients (5%) experienced bowel perforations. Conclusions: Combination of paclitaxel and bevacizumab is feasible and demonstrates an acceptable toxicity profile and a high response rate. These observations should be useful in planning future clinical trials with this combination therapy.

AB - Objective: To determine efficacy, toxicity, and survival in patients with recurrent epithelial ovarian cancer (EOC) receiving combination of weekly paclitaxel and biweekly bevacizumab (PB). Methods: We reviewed chemotherapy logs identifying all patients receiving combination PB. Toxicities were graded using CTCAEv3.0 criteria. Response rates (RR) were measured using RECIST criteria or by CA-125 levels per modified Rustin criteria. RR and progression-free survival (PFS) were determined and plotted using Kaplan-Meier survival analysis. Results: Fifty-one patients receiving at least two cycles of chemotherapy were evaluable for survival and 55 patients receiving one cycle of PB were evaluable in toxicity analysis. The mean number of previous regimens was four. The overall median PFS was 7 months and median OS was 12 months. The overall response rate (ORR) was 60% (CR 25% and PR 35%). Median PFS for complete and partial responders were 14 and 5 months respectively. Stable disease was seen in 26% with median PFS of 6 months. Thirteen experienced treatment delays for a variety of factors. The most G3/4 toxicities were fatigue (16%), hematologic (9%) and neurotoxicity (7%). Three patients (5%) experienced bowel perforations. Conclusions: Combination of paclitaxel and bevacizumab is feasible and demonstrates an acceptable toxicity profile and a high response rate. These observations should be useful in planning future clinical trials with this combination therapy.

KW - Biologics

KW - Chemotherapy

KW - Monoclonal antibodies

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=70350566692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350566692&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2009.08.032

DO - 10.1016/j.ygyno.2009.08.032

M3 - Article

C2 - 19804901

AN - SCOPUS:70350566692

VL - 115

SP - 396

EP - 400

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -